✦ LIBER ✦
Can the increasing number of newly developed leucine-rich repeat kinase 2 inhibitors validate or invalidate a potential disease-modifying therapeutic approach for Parkinson's disease?
✍ Scribed by Taymans, Jean-Marc
- Book ID
- 125550350
- Publisher
- Informa plc
- Year
- 2014
- Tongue
- English
- Weight
- 125 KB
- Volume
- 24
- Category
- Article
- ISSN
- 1354-3776
No coin nor oath required. For personal study only.